Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05971810

Perioperative Oral Decontamination and ImmunoNuTrition (POINT) in Elderly

The goal of this multicenter randomized controlled trial is to explore the efficacy of perioperative oral decontamination and immunonutrition supplement to prevent postoperative pulmonary complications in elderly patients(≥65 years) receiving elective non-cardiac operations. Participants will be either given immunonutrition supplement versus routine nutrition advice, and oral chlorhexidine decontamination versus routine oral care randomly. The two interventions will be compared with control groups separately regarding postoperative pulmonary complications and other outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Loading trial locations.

About this study

This study is a prospective, multicenter, two-by-two factorial randomized controlled trial evaluating the efficacy of immunonutrition supplementation and oral chlorhexidine decontamination. Patients aged 65 years and older who are scheduled for elective non-cardiac surgeries will be recruited. Participants will be excluded if they have contraindication to the intervention. The patients will be randomized into four groups in 1:1:1:1 ratio (oral decontamination vs routine oral care, immunonutrition supplementation vs routine nutrition advice). The primary outcome is the incidence of postoperative pulmonary complications within 7 days after surgery. Secondary outcomes include incidence of pneumonia, infectious complications, comprehensive complication index, postoperative functional recovery, length of hospital stay and hospital expense.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age≥65 years;
  • undergoing major non-cardiac surgery;
  • scheduled for general anesthesia and endotracheal intubation;
  • American Society of Anesthesiologists (ASA) physical status classification I-IV;
  • with intermediate to high risk of respiratory complications assessed by Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score;
  • informed consent obtained.

Exclusion criteria

  • emergency surgery;
  • preoperative pneumonia;
  • allergic to chlorhexidine;
  • severe hepatic/renal dysfunction, incapable of oral feeding, with autoimmune diseases, taking immunosuppressant or immunoregulation medications, or with other contraindication to immunonutrition supplementation;
  • expected intervention of immunonutrition<3 days.

Treatment and study plan

immunonutrition supplement of ORAL IMPACT™

Dietary Supplement

For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.

oral chlorhexidine decontamination

Other

For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.

Primary outcomes

  1. postoperative pulmonary complications

    Time frame: within 7 days after surgery

    composite outcome of postoperative pulmonary complications, including pneumonia, atelectasis, pneumothorax, bronchospasm, pleural effusion, hypoxemia, acute respiratory failure, prolonged mechanical ventilation, unplanned re-intubation,etc.

Secondary outcomes

  1. postoperative pneumonia

    Time frame: within 7days and 30 days after surgery

    defined according to the US Centers for Disease Control Definition

  2. postoperative pulmonary complications

    Time frame: within 30 days after surgery

    composite outcome of postoperative pulmonary complications, including pneumonia, atelectasis, pneumothorax, bronchospasm, pleural effusion, hypoxemia, acute respiratory failure, prolonged mechanical ventilation, unplanned re-intubation,etc.

  3. postoperative infectious complications

    Time frame: within 7days and 30 days after surgery

    composite outcome including surgical site infection, respiratory infection, urinary tract infection, intra-abdominal infection, blood stream infection, etc.

  4. postoperative complications

    Time frame: within 7days and 30 days after surgery

    defined using comprehensive complication index

  5. postoperative recovery

    Time frame: within 7days and 30 days after surgery

    assessed by 15-item quality of recovery questionnaire and WHO disability assessment schedule 2.0

  6. hospitalization expenses

    Time frame: upon hospital discharge, typically 1-2 weeks

    total expense during the hospital stay

  7. length of hospital stay

    Time frame: upon hospital discharge,typically 1-2 weeks

    days of in hospital stay

Study contacts

Contact information is provided by the study sponsor or research team.

Lu Che, Dr

CONTACT

[email protected]

69152020

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Collaborators

  • Fujian Provincial Hospital
  • Guizhou Provincial People's Hospital
  • Ningbo No.2 Hospital
  • Peking University International Hospital
  • Shenzhen Nanshan District Shekou People's Hospital
  • The Second Hospital of Hebei Medical University

Registry information

Official study title

Perioperative Oral Decontamination and ImmunoNuTrition (POINT) on Postoperative Pulmonary Complications in Elderly: a Multicenter Randomized Controlled Trial

Acronym: POINT

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 2, 2023
Registry last updated
Jan 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.